Clinical Outcomes after Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder with Squamous or Glandular Differentiation

Clinical Genitourinary Cancer

Volumn 14, Issue 1, 2016, Pages 82-88

  Zargar Shoshtari, Kamran ^a   Sverrisson, Einar F ^a   Sharma, Pranav ^a   Gupta, Shilpa ^a   Poch, Michael A ^a   Pow Sang, Julio M ^a   Spiess, Philippe E ^a   Sexton, Wade J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cystectomy carcinoma; Histology; Neoadjuvant therapy; Transitional Cell; Urinary bladder neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CYSTECTOMY; ENDOSCOPIC SURGERY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASMS, SQUAMOUS CELL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

AGED; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASMS, SQUAMOUS CELL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84952873822     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.08.006     Document Type: Article

References (30)

1. Clinical Practice Guidelines in Oncology, Version 2.2014. Bladder Cancer Version 2 2014 National Comprehensive Cancer Network (NCCN) Jenkintown, PA
2. J.A. Witjes, E. Comperat, N.C. Cowan, and et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines Eur Urol 65 2014 778 792
3. H.B. Grossman, R.B. Natale, C.M. Tangen, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
4. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
5. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 205 discussion 205-6
6. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, and et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
7. A. Sherif, L. Holmberg, E. Rintala, and et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297 303
8. P.J. Gray, S.A. Fedewa, W.U. Shipley, and et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base Eur Urol 63 2013 823 829
9. G. Gandaglia, I. Popa, F. Abdollah, and et al. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study Eur Urol 66 2014 561 568
10. W. Kassouf, P.E. Spiess, G.A. Brown, and et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors Eur Urol 52 2007 769 774
11. H. Linardou, G. Aravantinos, E. Efstathiou, and et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group Urology 64 2004 479 484
12. L. Dogliotti, G. Carteni, S. Siena, and et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial Eur Urol 52 2007 134 141
13. J. Bellmunt, A. Ribas, N. Eres, and et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 1997 1966 1972
14. A.F. Kantor, P. Hartge, R.N. Hoover, and J.F. Fraumeni Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder Cancer Res 48 1988 3853 3855
15. P.C. Black, G.A. Brown, and C.P. Dinney The impact of variant histology on the outcome of bladder cancer treated with curative intent Urol Oncol 27 2009 3 7
16. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 2010 1471 1474
17. F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, I. Vavassori, and S. Barni Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis Eur Urol 65 2014 350 357
18. R. Rosenblatt, A. Sherif, E. Rintala, and et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
19. H. Zargar, P.N. Espiritu, A.S. Fairey, and et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 67 2015 241 249
20. E. Scosyrev, B.W. Ely, E.M. Messing, and et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710) BJU Int 108 2011 693 699
21. A.P. Mitra, C.C. Bartsch, G. Bartsch Jr., G. Miranda, E.C. Skinner, and S. Daneshmand Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis Urol Oncol 32 2014 117 127
22. E. Xylinas, M. Rink, B.D. Robinson, and et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy Eur J Cancer 49 2013 1889 1897
23. R. Petrioli, B. Frediani, A. Manganelli, and et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study Cancer 77 1996 344 351
24. A.C. James, F.C. Lee, J.P. Izard, and et al. Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer Clin Genitourin Cancer 12 2014 287 291
25. S.E. Lee, I.G. Jeong, J.H. Ku, C. Kwak, E. Lee, and J.S. Jeong Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor Urology 63 2004 873 877 discussion 877
26. C. Rodel, G.G. Grabenbauer, R. Kuhn, and et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 2002 3061 3071
27. W.U. Shipley, G.R. Prout Jr., S.D. Kaufman, and T.L. Perrone Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation Cancer 60 3 suppl 1987 514 520
28. Q.L. Zhang, and D. Rothenbacher Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 2008 117
29. A.P. Mitra, E.C. Skinner, G. Miranda, and S. Daneshmand A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer BJU Int 111 2013 240 248
30. P.I. Karakiewicz, S.F. Shariat, G.S. Palapattu, and et al. Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 2006 1254 1260 discussion 1261-52